// App-Quantinova.ai

: Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Researchers

Presenter

  • Sairah Ahmed

Principal Investigators

  • Ian W. Flinn

  • Matthew Mei

  • Peter A. Riedell

  • Philippe Armand

  • Natalie S. Grover

  • Renu Balyan

  • Cliff Ding

  • Aung Myo

  • Ivan D. Horak

  • Helen E. Heslop

Medical Centers

  • Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Tessa Therapeutics, Singapore, Singapore

  • Division of Lymphoma, City of Hope Medical Center, Duarte, CA

  • Department of Lymphoma/Myeloma and Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX

  • Section of Hematology/Oncology, University of Chicago, Chicago, IL

  • Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

  • Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX

Locations

  • United States

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • Cluster of Differentiation 30

  • Circulating DNA

Drug/Treatment

  • brentuximab vedotin

  • Adcetris

  • Bendamustine

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Safety

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved